Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANCEF vs ANSPOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Respiratory tract infections,Urinary tract infections,Skin and skin structure infections,Biliary tract infections,Bone and joint infections,Genital infections,Septicemia,Endocarditis,Perioperative prophylaxis
FDA-approved: Treatment of respiratory tract infections, otitis media, skin and skin structure infections, bone infections, genitourinary tract infections caused by susceptible bacteria.,Off-label: Prosthetic joint infections, dental infections, endocarditis prophylaxis.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (Cr Cl <10 m L/min)
Not significantly metabolized; primarily excreted unchanged by renal tubular secretion.
Cephalexin is not extensively metabolized; it is primarily excreted unchanged in the urine. Minor hepatic metabolism may occur.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
80-85% bound to serum albumin.
10–20% bound to serum albumin
0.14-0.17 L/kg; primarily extracellular fluid.
0.13–0.22 L/kg; indicates distribution primarily into extracellular fluid
IM: ~100% (well absorbed); IV: 100%.
Oral: 75–90% (well absorbed); IM: 100%
Cr Cl >55 m L/min: 1-2 g every 8 h. Cr Cl 35-54: 1-2 g every 8-12 h. Cr Cl 11-34: 1-2 g every 12 h. Cr Cl <10: 1-2 g every 24-48 h. Hemodialysis: 1-2 g after dialysis.
Cr Cl 10-50 m L/min: 250 mg every 12-24 hours. Cr Cl <10 m L/min: 250 mg every 24-48 hours.
No adjustment required for hepatic impairment.
No specific adjustment recommended; monitor for adverse effects in severe impairment.
Infants and children 1 month and older: 25-50 mg/kg/day IV/IM divided every 8 h; severe infections: 100 mg/kg/day divided every 6-8 h. Maximum 6 g/day.
12.5-25 mg/kg orally every 6 hours; maximum 50 mg/kg/day.
No specific adjustment; use renal function-based dosing as per renal_adjustment.
Start at lower end of dosing range; monitor renal function and adjust based on Cr Cl.
No FDA boxed warnings.
No FDA boxed warning exists for cephalexin.
Hypersensitivity reactions, including anaphylaxis, especially in patients with penicillin allergy,Clostridium difficile-associated diarrhea,Renal impairment: dose adjustment required,Prolonged use may result in superinfection,Seizures at high doses in renal impairment
Hypersensitivity reactions including anaphylaxis.,Clostridioides difficile-associated diarrhea (CDAD).,Dosage adjustment required in renal impairment.,Seizures with high doses or renal failure.,Potential for superinfection with prolonged use.
Hypersensitivity to cefazolin or other cephalosporins,History of severe immediate hypersensitivity reaction (e.g., anaphylaxis) to penicillins
Known hypersensitivity to cephalosporins or penicillins (cross-sensitivity).,Previous immediate hypersensitivity reaction to penicillins.
No significant food interactions. Cefazolin may be administered with or without food. However, alcohol should be avoided due to potential disulfiram-like reaction (cephalosporin side chain effect).
Iron-fortified infant formula and iron supplements may reduce absorption; take at least 2 hours apart. No other significant food interactions. Avoid alcohol.
No evidence of teratogenicity in animal studies. Crosses placenta. Use only if clearly needed during pregnancy. First trimester: limited data, no known malformations. Second and third trimesters: no known fetal harm.
Cefradine (ANSPOR) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and adequate well-controlled studies in pregnant women are lacking. No evidence of teratogenicity; however, caution is advised. First trimester: no known risk; second and third trimesters: no known fetal adverse effects.
Excreted in breast milk in low concentrations (M/P ratio unknown, likely low). Considered compatible with breastfeeding due to poor oral bioavailability in infants.
Cefradine is excreted into human breast milk in low concentrations. M/P ratio is approximately 0.12–0.20. Considered compatible with breastfeeding by the American Academy of Pediatrics; however, monitor infant for potential diarrhea or allergic reaction.
No dosage adjustment recommended for pregnancy. Increased clearance in pregnancy may necessitate higher doses in severe infections, but standard dosing is typically effective.
Increased renal clearance during pregnancy may lower serum concentrations of cefradine. Standard dosing (250–500 mg every 6 hours) is generally adequate; however, for severe infections, consider higher doses or more frequent administration based on clinical response. No specific dose adjustment is routinely recommended, but monitoring therapeutic efficacy is advised.
Cefazolin (Ancef) is a first-generation cephalosporin with excellent gram-positive coverage, often used for surgical prophylaxis. It has poor CSF penetration, so it is not suitable for meningitis. Cross-allergenicity with penicillins occurs in approximately 10% of patients. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
ANSPOR (cefdinir) is a third-generation oral cephalosporin with activity against Gram-positive and Gram-negative bacteria. It is stable in the presence of some beta-lactamases. Dose adjustment required for Cr Cl <30 m L/min. Avoid use in patients with immediate hypersensitivity to penicillins due to cross-reactivity (approx 10%). Administer with iron supplements or iron-fortified infant formula at least 2 hours apart to reduce chelation. Suspension should be refrigerated and discarded after 10 days.
Take exactly as prescribed, even if you feel better.,Complete the full course to prevent resistance.,Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately.,May cause diarrhea; contact your doctor if severe or persistent.,Avoid alcohol during treatment and for 48 hours after last dose (disulfiram-like reaction possible but rare).
Take exactly as prescribed, even if you feel better.,Complete the full course of therapy.,If using suspension, shake well before each dose. Refrigerate and discard after 10 days.,Avoid alcohol while taking this medication.,Notify your doctor if you experience diarrhea, rash, or signs of allergic reaction.,Take iron supplements or iron-fortified infant formula at least 2 hours apart from ANSPOR.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANCEF vs ANSPOR, answered by our medical review team.
ANCEF is a Cephalosporin Antibiotic that works by First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.. ANSPOR is a Cephalosporin Antibiotic that works by Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANCEF and ANSPOR depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANCEF is: 1-2 g IV/IM every 8 hours; maximum 6 g/day.. The standard adult dose of ANSPOR is: 250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANCEF and ANSPOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANCEF is classified as Category C. No evidence of teratogenicity in animal studies. Crosses placenta. Use only if clearly needed during pregnancy. First trimester: limited data, no known malformations. Second and th. ANSPOR is classified as Category C. Cefradine (ANSPOR) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and adequate well-controlled studies in pregnant women are lacking. N. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.